Upadacitinib therapy in refractory inflammatory myositis: a case series of 10 patients.

Published in: RMD open (2024)

Upadacitinib appears to be effective in targeting cutaneous manifestations of refractory inflammatory DM. Further research is still needed to validate its efficacy on a broader population scale.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
oxidative stress
chronic kidney disease
peritoneal dialysis
prognostic factors
stem cells
cancer therapy
metabolic syndrome
drug delivery
smoking cessation
replacement therapy